LifeVantage Co. (NASDAQ:LFVN - Get Free Report)'s stock price passed above its two hundred day moving average during trading on Monday . The stock has a two hundred day moving average of $15.57 and traded as high as $17.64. LifeVantage shares last traded at $17.04, with a volume of 153,399 shares trading hands.
Analyst Ratings Changes
LFVN has been the subject of a number of analyst reports. Lake Street Capital began coverage on shares of LifeVantage in a research note on Thursday, December 19th. They set a "buy" rating and a $26.00 target price for the company. Craig Hallum began coverage on LifeVantage in a research report on Tuesday, January 14th. They issued a "buy" rating and a $35.00 price objective for the company.
Check Out Our Latest Stock Report on LifeVantage
LifeVantage Stock Down 5.3 %
The stock has a market capitalization of $193.57 million, a price-to-earnings ratio of 27.54 and a beta of 0.74. The company has a 50 day simple moving average of $19.65 and a 200-day simple moving average of $15.64.
LifeVantage (NASDAQ:LFVN - Get Free Report) last issued its earnings results on Wednesday, February 5th. The company reported $0.22 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.14 by $0.08. LifeVantage had a net margin of 3.46% and a return on equity of 34.29%.
LifeVantage Announces Dividend
The company also recently announced a quarterly dividend, which was paid on Monday, March 17th. Investors of record on Monday, March 3rd were given a $0.04 dividend. This represents a $0.16 dividend on an annualized basis and a yield of 1.04%. The ex-dividend date was Monday, March 3rd. LifeVantage's payout ratio is 28.57%.
Insider Buying and Selling
In other news, Director Raymond B. Greer sold 8,000 shares of the company's stock in a transaction that occurred on Monday, February 10th. The stock was sold at an average price of $20.15, for a total transaction of $161,200.00. Following the transaction, the director now directly owns 99,288 shares of the company's stock, valued at $2,000,653.20. This represents a 7.46 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. 20.65% of the stock is owned by company insiders.
Institutional Trading of LifeVantage
A number of hedge funds and other institutional investors have recently bought and sold shares of the business. Barclays PLC grew its holdings in shares of LifeVantage by 38.2% during the third quarter. Barclays PLC now owns 41,966 shares of the company's stock valued at $507,000 after buying an additional 11,608 shares during the last quarter. HighTower Advisors LLC bought a new stake in LifeVantage during the 3rd quarter worth approximately $638,000. Ritholtz Wealth Management raised its stake in shares of LifeVantage by 65.2% in the fourth quarter. Ritholtz Wealth Management now owns 47,348 shares of the company's stock worth $830,000 after purchasing an additional 18,682 shares during the last quarter. Copeland Capital Management LLC bought a new position in shares of LifeVantage in the fourth quarter valued at approximately $65,000. Finally, Ancora Advisors LLC bought a new position in shares of LifeVantage in the fourth quarter valued at approximately $1,138,000. Institutional investors own 35.32% of the company's stock.
LifeVantage Company Profile
(
Get Free Report)
LifeVantage Corporation engages in the identification, research, development, formulation, and sale of advanced nutrigenomic activators, dietary supplements, nootropics, pre- and pro-biotics, weight management, skin and hair care, bath and body, and targeted relief products. It offers Protandim, a dietary supplement; LifeVantage Omega+, a dietary supplement that combines DHA and EPA Omega-3 fatty acids, Omega-7 fatty acids, and vitamin D3; LifeVantage ProBio, a dietary supplement to support gut health; PhysIQ, a weight management system; LifeVantage IC Bright, a supplement to support eye and brain health, reduce eye fatigue and strain, supports cognitive functions, and support normal sleep patterns; Petandim for Dogs, a supplement to combat oxidative stress in dogs; and Axio, a nootropic energy drink mix.
See Also
Before you consider LifeVantage, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and LifeVantage wasn't on the list.
While LifeVantage currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Which stocks are likely to thrive in today's challenging market? Enter your email address and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
